SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001104659-23-024013
Filing Date
2023-02-22
Accepted
2023-02-22 06:41:31
Documents
13
Period of Report
2023-02-20
Items
Item 8.01: Other Events
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 FORM 8-K tm237246d1_8k.htm   iXBRL 8-K 32182
2 EXHIBIT 2.1 tm237246d1_ex2-1.htm EX-2.1 24306
  Complete submission text file 0001104659-23-024013.txt   238889

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA ruby-20230220.xsd EX-101.SCH 3033
4 XBRL TAXONOMY EXTENSION LABEL LINKBASE ruby-20230220_lab.xml EX-101.LAB 34476
5 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE ruby-20230220_pre.xml EX-101.PRE 22595
7 EXTRACTED XBRL INSTANCE DOCUMENT tm237246d1_8k_htm.xml XML 3645
Mailing Address C/O VERDOLINO & LOWEY, P.C. 124 WASHINGTON STREET, SUITE 101 FOXBORO MA 02035
Business Address C/O VERDOLINO & LOWEY, P.C. 124 WASHINGTON STREET, SUITE 101 FOXBORO MA 02035 617-679-9600
Rubius Therapeutics, Inc. (Filer) CIK: 0001709401 (see all company filings)

IRS No.: 042688109 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-38586 | Film No.: 23650481
SIC: 2836 Biological Products, (No Diagnostic Substances)